Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SEATTLE, Feb. 14, 2017 -- Nohla Therapeutics Inc. (Nohla), a leading innovator in the development of universal donor cellular therapies for the treatment of patients with blood cancers, announced today that it will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Dr. Colleen Delaney, Nohla’s Scientific Founder and Chief Medical Officer, is scheduled to present on Tuesday, March 7th at 2:00pm ET.
Dr. Delaney’s presentation will provide an overview of the Company’s ex vivo expansion platform, which enables expansion and directed differentiation of cord blood stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching). In addition, Dr. Delaney will profile Nohla’s two lead programs evaluating the ability of these products to reduce infection and other complications of neutropenia in multi-center, randomized clinical trials: a Phase IIb study in the setting of cord blood transplant and a global Phase II study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML).
About Nohla Therapeutics
Nohla Therapeutics Inc. (Nohla) is a clinical stage company dedicated to the development of universal donor cellular therapies for the treatment of patients with life threatening blood cancers. The Company is leveraging a platform developed over the past two decades at Fred Hutchinson Cancer Research Center which enables the ex vivo expansion and directed differentiation of cord blood stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching). Nohla is evaluating the ability of these “off-the-shelf” cryopreserved expanded cell products to reduce infection and other complications of neutropenia in several clinical settings including two lead programs involving multi-center, randomized clinical trials: a Phase IIb study in the setting of cord blood transplant and a global Phase II study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML). Nohla is supported by top-tier healthcare dedicated institutional investors including ARCH Venture Partners, 5AM Ventures, and Jagen Group.
For more information, please contact: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 [email protected] Media Esther Cuno Director, Corporate Communications +1 206 519 5313 [email protected]
